Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | -99.76% |
Apr. 02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
2023 | Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 24.41 | 3.493 | 12.07 | 59.48 | 60.97 | 9.041 |
Enterprise Value (EV) 1 | 25.05 | 1.696 | 5.313 | 57.34 | 44.78 | 8.253 |
P/E ratio | - | - | -0.23 x | -2.95 x | -18.9 x | -0.28 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 4.82 x | 1.07 x | 2.18 x | 2.17 x | 1 x | 0.35 x |
EV / Revenue | 4.94 x | 0.52 x | 0.96 x | 2.09 x | 0.73 x | 0.32 x |
EV / EBITDA | -1.22 x | -0.07 x | -0.24 x | -3.99 x | -50.9 x | -0.27 x |
EV / FCF | -1.9 x | -0.12 x | -0.34 x | -3.89 x | 22.7 x | -0.89 x |
FCF Yield | -52.5% | -802% | -291% | -25.7% | 4.4% | -112% |
Price to Book | - | 1.31 x | 1.4 x | 2.51 x | 1.63 x | 1.02 x |
Nbr of stocks (in thousands) | 3.91 | 13.5 | 141 | 447 | 561 | 569 |
Reference price 2 | 6,245 | 258.0 | 85.80 | 133.2 | 108.6 | 15.90 |
Announcement Date | 3/28/18 | 3/29/19 | 3/27/20 | 3/31/21 | 4/5/22 | 4/17/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 5.069 | 3.25 | 5.529 | 27.46 | 61.25 | 25.86 |
EBITDA 1 | -20.6 | -23.46 | -22.13 | -14.38 | -0.879 | -30.33 |
EBIT 1 | -21.17 | -24.26 | -23.06 | -15.47 | -2.409 | -31.98 |
Operating Margin | -417.76% | -746.35% | -417.05% | -56.33% | -3.93% | -123.69% |
Earnings before Tax (EBT) 1 | -21.61 | -24.57 | -25.14 | -17.81 | -2.699 | -32.21 |
Net income 1 | -21.61 | -24.57 | -25.14 | -17.81 | -2.824 | -32.09 |
Net margin | -426.42% | -755.98% | -454.69% | -64.84% | -4.61% | -124.09% |
EPS | - | - | -366.8 | -45.11 | -5.734 | -56.78 |
Free Cash Flow 1 | -13.16 | -13.61 | -15.48 | -14.75 | 1.971 | -9.222 |
FCF margin | -259.58% | -418.73% | -280.01% | -53.72% | 3.22% | -35.66% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/28/18 | 3/29/19 | 3/27/20 | 3/31/21 | 4/5/22 | 4/17/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 12.05 | 17.47 | 13.93 | 19.94 | 10.61 | 5.587 | -10.28 | 0.673 | 0.589 |
EBITDA | - | - | - | - | - | - | - | - | - | - |
EBIT | - | -1.748 | 0.5016 | -2.776 | -2.707 | -5.097 | -5.577 | -18.6 | - | - |
Operating Margin | - | -14.51% | 2.87% | -19.93% | -13.57% | -48.04% | -99.82% | 180.88% | - | - |
Earnings before Tax (EBT) | - | -1.827 | 0.427 | -2.846 | -2.768 | -5.252 | -5.545 | -18.65 | - | - |
Net income | 2.599 | -1.827 | 0.427 | -2.971 | -2.768 | -5.252 | -5.545 | -18.52 | - | - |
Net margin | - | -15.17% | 2.44% | -21.33% | -13.88% | -49.5% | -99.25% | 180.09% | - | - |
EPS | 5.700 | -15.30 | 0.9000 | -5.400 | -4.800 | -9.300 | -9.900 | -32.70 | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 5/12/21 | 8/16/21 | 11/15/21 | 4/6/22 | 5/23/22 | 11/10/22 | 11/21/22 | 4/17/23 | 5/10/23 | 8/14/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.64 | - | - | - | - | - |
Net Cash position 1 | - | 1.8 | 6.76 | 2.14 | 16.2 | 0.79 |
Leverage (Debt/EBITDA) | -0.0312 x | - | - | - | - | - |
Free Cash Flow 1 | -13.2 | -13.6 | -15.5 | -14.8 | 1.97 | -9.22 |
ROE (net income / shareholders' equity) | -2,211% | -1,133% | -353% | -102% | -9.23% | -138% |
ROA (Net income/ Total Assets) | -177% | -188% | -109% | -29.7% | -2.79% | -43.8% |
Assets 1 | 12.21 | 13.07 | 23.1 | 60.03 | 101.2 | 73.27 |
Book Value Per Share | - | 197.0 | 61.40 | 53.10 | 66.70 | 15.60 |
Cash Flow per Share | - | 222.0 | 51.00 | 32.20 | 51.40 | 22.70 |
Capex 1 | 1.4 | 0.15 | 0.74 | 0.87 | 1.57 | 0.81 |
Capex / Sales | 27.62% | 4.47% | 13.3% | 3.16% | 2.57% | 3.12% |
Announcement Date | 3/28/18 | 3/29/19 | 3/27/20 | 3/31/21 | 4/5/22 | 4/17/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-99.76% | 262 | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.29B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- BIOCQ Stock
- Financials Biocept, Inc.